SCHEMBL3095474

SCHEMBL3095474

Cc1oc(-c2cccnc2)cc1C(Nc1ccc(C(=O)O)cc1)C1CCCCC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RCE1 Q9Y256 2/20 0.51
MKNK1 Q9BUB5 1/20 0.40
MKNK2 Q9HBH9 1/20 0.40
NAMPT P43490 1/20 0.39
CDK2 P24941 2/20 0.39
GSK3B P49841 2/20 0.39
MMP13 P45452 1/20 0.38
RAB9A P51151 2/20 0.38
MEN1 O00255 1/20 0.38
ALDH1A1 P00352 1/20 0.38
KMT2A Q03164 1/20 0.38
NPC1 O15118 1/20 0.38
DNM1L O00429 1/20 0.37
KDM4E B2RXH2 2/20 0.37
LDHA P00338 1/20 0.37
LDHB P07195 1/20 0.37
TP53 P04637 1/20 0.37
MAPK1 P28482 1/20 0.37
HSD17B10 Q99714 1/20 0.37
KMO O15229 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3094894 0.90 RCE1 (0.49) RCE1MMP13RAB9AMEN1ALDH1A1
SCHEMBL3107553 0.89 RCE1 (0.49) RCE1MMP13RAB9AMEN1ALDH1A1
SCHEMBL3101341 0.89 RCE1 (0.48) RCE1RAB9AMEN1ALDH1A1KMT2A
SCHEMBL3106902 0.88 RCE1 (0.49) RCE1GSK3BMMP13RAB9AMEN1
SCHEMBL3109938 0.88 RCE1 (0.45) RCE1RAB9AMEN1ALDH1A1KMT2A
SCHEMBL3110100 0.88 GCG (0.46) RCE1NAMPTMMP13
SCHEMBL3101072 0.87 AKR1C3 (0.41) RCE1NAMPTCDK2GSK3BMMP13
SCHEMBL3106785 0.86 ALDH1A1 (0.47) RCE1RAB9AMEN1ALDH1A1KMT2A
SCHEMBL3111558 0.85 RCE1 (0.43) RCE1MKNK1MKNK2MMP13RAB9A
SCHEMBL3089854 0.85 RCE1 (0.46) RCE1RAB9AMEN1ALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2210876-B1 HETEROCYCLIC COMPOUND AS GLUCAGON ANTAGONIST TAKEDA PHARMACEUTICAL (JP) 2015-05-20 EP disclosed
US-8309580-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-11-13 US disclosed
US-20100256156-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-10-07 US disclosed
EP-2210876-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-07-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256156-A1 HETEROCYCLIC COMPOUND GLP1R, GPR119, GCGR RCE1 3126/4885MKNK1 3424/4885MKNK2 3480/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.